ALFA Finder| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 21% YoY revenue growth driven by volume expansion and genomics. |
|---|---|
| Margins | EBITDA margins expanded to 36%; mature centers at 40.9%. |
| Demand visibility | Strong, specifically in specialized genomics and pathology across Eastern India. |
| Management confidence | Confident, highlighting strong execution in expansion and genomics adoption. |
Growth
Revenue grew 21% YoY; genomics vertical surged 136% YoY; EBITDA margins expanded to 36% from 34%.
Outlook
Management guides for 15% revenue growth for FY27 and plans to reach 100 centers by FY28.
Risks
Seasonal weakness in Q3; regional concentration in Eastern India; margin pressure from rapid new center ramp-ups.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 21% (= BEAT)
- Guided 33% EBITDA margin → delivered 36% (= BEAT)
- Guided 5 hubs and 8 spokes addition → delivered 10 centers (= BEAT)
Partly delivered
- Guided INR 70Cr capex → delivered INR 70-80Cr range (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: SURAKSHA. Summary written with AI assistance from the document.
Suraksha Diagnostic Ltd: key numbers
- Share price
- ₹357.85
- Market cap
- ₹1,864 Cr
- Revenue (annual)
- ₹310.4 Cr
- Net profit (annual)
- ₹32.19 Cr
- P/E (TTM)
- 44.6×Sector 54.5×
- Promoter holding
- 49.10%+0.00% QoQ
- FII holding
- 13.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suraksha Diagnostic Ltd
All →Suraksha Diagnostic Results Update
Suraksha Diagnostic reported H1 FY27 total income of ₹1,893.09 million and PAT of ₹277.96 million, up 54% year-on-year. The press release accompanies its unaudited quarterly results.
Suraksha Diagnostic Q2 FY27 Results: Net Profit ₹15 Cr, Up 70.5% YoY
Suraksha Diagnostic Ltd reported revenue from operations of ₹99.1 Cr (+25.9% YoY) and net profit of ₹15 Cr (+70.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹15 Cr · +70.5% YoY
Suraksha Diagnostic Board Meeting Date
Suraksha Diagnostic will hold a board meeting on 10 November 2026 to consider September quarter results and other business. Trading window closes from 1 October to 12 November 2026.
Suraksha Diagnostic Other Announcement
Suraksha Diagnostic notified that RTA KFin Technologies is moving its corporate office to Kokapet, Hyderabad from 1 December 2026, with the registered office unchanged. The change is administrative and affects only the RTA's correspondence address.
Suraksha Diagnostic Legal & Regulatory
Suraksha Diagnostic disclosed a one-day delay in shareholding pattern filing, leading to a Rs. 2,360 fine. The Board has noted remedial measures to prevent future recurrence.
Suraksha Diagnostic Management Change
Suraksha Diagnostic has appointed Ms. Shreya Arora as Company Secretary and Compliance Officer, effective October 14, 2026.